Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: A cluster-randomized trial in primary care

Journal of Allergy and Clinical Immunology

Volumn 135, Issue 3, 2015, Pages 682-688.e11

  Honkoop, Persijn J ^a   Loijmans, Rik J B ^b   Termeer, Evelien H ^c   Snoeck Stroband, Jiska B ^a   Van Den Hout, Wilbert B ^a   Bakker, Moira J ^a   Assendelft, Willem J J ^a,c   Ter Riet, Gerben ^b   Sterk, Peter J ^b   Schermer, Tjard R J ^c   Sont, Jacob K ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

asthma control; asthma exacerbations; cost effectiveness; fraction of exhaled nitric oxide; online decision support; Quality of life

Indexed keywords

BECLOMETASONE; CORTICOSTEROID; MONTELUKAST; NITRIC OXIDE; ANTIASTHMATIC AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; ASTHMA; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DECISION SUPPORT SYSTEM; EMERGENCY CARE; FEMALE; FOLLOW UP; GENERAL PRACTICE; HEALTH CARE PERSONNEL; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; ADOLESCENT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE MANAGEMENT; DRUG MONITORING; ECONOMICS; EXHALATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL MARKERS; COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; DRUG MONITORING; EXHALATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES;

EID: 84924407907     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2014.07.016     Document Type: Article

References (60)

1. M. Masoli, D. Fabian, S. Holt, and R. Beasley Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report Allergy 59 2004 469 478
2. H. Chen, M.K. Gould, P.D. Blanc, D.P. Miller, T.V. Kamath, and J.H. Lee Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease J Allergy Clin Immunol 120 2007 396 402
3. V. Siroux, A. Boudier, J.M. Anto, L. Cazzoletti, S. Accordini, and J. Alonso Quality-of-life and asthma-severity in general population asthmatics: results of the ECRHS II study Allergy 63 2008 547 554
4. P.W. Sullivan, K.L. Smith, V.H. Ghushchyan, D.R. Globe, S. Lin, and G. Globe Asthma in USA: its impact on health-related quality of life J Asthma 50 2013 891 899
5. U.K. Asthma Annual report and accounts 2013 2013 London
6. R. Gupta, A. Sheikh, D.P. Strachan, and H.R. Anderson Burden of allergic disease in the UK: secondary analyses of national databases Clin Exp Allergy 34 2004 520 526
7. National Heart, Lung, and Blood Institute National Asthma Education and Prevention Program (NAEPP) Expert panel report 3 Guidelines for the diagnosis and management of asthma 2007 National Heart, Lung, and Blood Institute Bethesda
8. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. Available at: http://www.ginasthma.org/. Accessed August 2, 2014.
9. British Thoracic Society Scottish Intercollegiate Guidelines Network British Guideline on the management of asthma A national clinical guideline 2008 British Thoracic Society London
10. The Dutch General Practice Society (NHG) guideline Asthma in adults 2007 Dutch General Practice Society Utrecht, The Netherlands
11. H.K. Reddel, D.R. Taylor, E.D. Bateman, L.P. Boulet, H.A. Boushey, and W.W. Busse An official American Thoracic Society/European respiratory society statement: asthma control and exacerbations Am J Respir Crit Care Med 180 2009 59 99
12. K.R. Chapman, L.P. Boulet, R.M. Rea, and E. Franssen Suboptimal asthma control: prevalence, detection and consequences in general practice Eur Respir J 31 2008 320 325
13. L.S. Gold, N. Smith, F.C. Allen-Ramey, R.A. Nathan, and S.D. Sullivan Associations of patient outcomes with level of asthma control Ann Allergy Asthma Immunol 109 2012 260 265
14. L. van den Nieuwenhof, T. Schermer, P. Eysink, E. Halet, C. van Weel, and P. Bindels Can the Asthma Control Questionnaire be used to differentiate between patients with controlled and uncontrolled asthma symptoms? A pilot study Fam Pract 23 2006 674 681
15. H. Powell, and P.G. Gibson Inhaled corticosteroid doses in asthma: an evidence-based approach Med J Aust 178 2003 223 225
16. F. Lapi, A. Kezouh, S. Suissa, and P. Ernst The use of inhaled corticosteroids and the risk of adrenal insufficiency Eur Respir J 42 2013 79 86
17. S.J. Szefler, H. Mitchell, C.A. Sorkness, P.J. Gergen, G.T. O'Connor, and W.J. Morgan Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomized controlled trial Lancet 372 2008 1065 1072
18. A.D. Smith, J.O. Cowan, K.P. Brassett, G.P. Herbison, and D.R. Taylor Use of exhaled nitric oxide measurements to guide treatment in chronic asthma N Engl J Med 352 2005 2163 2173
19. I.D. Pavord, and D. Shaw The use of exhaled nitric oxide in the management of asthma J Asthma 45 2008 523 531
20. H. Powell, V.E. Murphy, D.R. Taylor, M.J. Hensley, K. McCaffery, and W. Giles Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial Lancet 378 2011 983 990
21. D. Price, J. Berg, and P. Lindgren An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom Allergy 64 2009 431 438
22. P.J. Honkoop, R.J. Loymans, E.H. Termeer, J.B. Snoeck-Stroband, M.J. Bakker, and W.J. Assendelft Asthma Control Cost-Utility Randomized Trial Evaluation (ACCURATE): the goals of asthma treatment BMC Pulm Med 11 2011 53
23. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005 Am J Respir Crit Care Med 171 2005 912 930
24. H. Dressel, J. Reichert, U. Ochmann, R. Petru, P. Angerer, and O. Holz Exhaled nitric oxide: independent effects of atopy, smoking, respiratory tract infection, gender and height Respir Med 102 2008 962 969
25. L.M. Lamers, J. McDonnell, P.F. Stalmeier, P.F. Krabbe, and J.J. Busschbach The Dutch tariff: results and arguments for an effective design for national EQ-5d validation studies Health Econ 15 2006 1121 1132
26. T.R. Schermer, B.P. Thoonen, R.P. Akkermans, R.P. Grol, H.T. Folgering, and C. van Weel Randomized controlled economic evaluation of asthma self-management in primary healthcare Am J Respir Crit Care Med 166 2002 1062 1072
27. Purchasing Parity Index; 2013. Available at: http://stats.oecd.org/index.aspx?datasetcode=sna-table4#. Accessed January 22, 2014.
28. E.F. Juniper, A.S. Buist, F.M. Cox, P.J. Ferrie, and D.R. King Validation of a standardized version of the Asthma Quality of Life Questionnaire Chest 115 1999 1265 1270
29. L. Fialko, P.A. Garety, E. Kuipers, G. Dunn, P.E. Bebbington, and D. Fowler A large-scale validation study of the Medication Adherence Rating Scale (MARS) Schizophr Res 100 2008 53 59
30. Foundation for Pharmaceutical Statistics/Stichting Farmaceutische Kengetallen (SFK). Available at: www.sfk.nl. Accessed September 15, 2013.
31. College voor Zorgverkeringen. Farmacotherapeutisch Kompas. Available at: www.fk.cvz.nl. Accessed May 20, 2009.
32. A.A. Stinnett, and J. Mullahy Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis Med Decis Making 18 1998 S68 S80
33. J.D. Campbell, D.K. Blough, and S.D. Sullivan Comparison of guideline-based control definitions and associations with outcomes in severe or difficult-to-treat asthma Ann Allergy Asthma Immunol 101 2008 474 481
34. K.J. Mortimer, L.J. Tata, C.J. Smith, J. West, T.W. Harrison, and A.E. Tattersfield Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study Thorax 61 2006 405 408
35. R.S. Hewitt, C.M. Modrich, J.O. Cowan, G.P. Herbison, and D.R. Taylor Outcomes using exhaled nitric oxide measurements as an adjunct to primary care asthma management Prim Care Respir J 18 2009 320 327
36. W.J. Calhoun, B.T. Ameredes, T.S. King, N. Icitovic, E.R. Bleecker, and M. Castro Comparison of physician-, biomarker-,and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial JAMA 308 2012 987 997
37. J.C. De Jongste, S. Carraro, W.C. Hop, and E. Baraldi Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma Am J Respir Crit Care Med 179 2009 93 97
38. D.E. Shaw, M.A. Berry, M. Thomas, R.H. Green, C.E. Brightling, and A.J. Wardlaw The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial Am J Respir Crit Care Med 176 2007 231 237
39. H.L. Petsky, C.J. Cates, T.J. Lasserson, A.M. Li, C. Turner, and J.A. Kynaston A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils) Thorax 67 2012 199 208
40. P.G. Gibson Using fractional exhaled nitric oxide to guide asthma therapy: design and methodological issues for ASthma TReatment ALgorithm studies Clin Exp Allergy 39 2009 478 490
41. E.D. Bateman, H.A. Boushey, J. Bousquet, W.W. Busse, T.J.H. Clark, and R.A. Pauwels Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study Am J Respir Crit Care Med 170 2004 836 844
42. S. Accordini, A.G. Corsico, M. Braggion, M.W. Gerbase, D. Gislason, and A. Gulsvik The cost of persistent asthma in Europe: an international population based study in adults Int Arch Allergy Immunol 160 2013 93 101
43. A.E. Lucas, F.J. Smeenk, I.J. Smeele, and O.P. van Schayck Diagnostic accuracy of primary care asthma/COPD working hypotheses, a real life study Respir Med 106 2012 1158 1163
44. E.F. Juniper, K. Svensson, A.C. Mork, and E. Stahl Measurement properties and interpretation of three shortened versions of the Asthma Control Questionnaire Respir Med 99 2005 553 558
45. P. Haldar, I.D. Pavord, D.E. Shaw, M.A. Berry, M. Thomas, and C.E. Brightling Cluster analysis and clinical asthma phenotypes Am J Respir Crit Care Med 178 2008 218 224
46. S.E. Wenzel Asthma: defining of the persistent adult phenotypes Lancet 368 2006 804 813
47. D.B. Rubin Multiple imputation for non-response in surveys 1987 Wiley New York
48. E.F. Juniper, P.M. O'Byrne, G.H. Guyatt, P.J. Ferrie, and D.R. King Development and validation of a questionnaire to measure asthma control Eur Respir J 14 1999 902 907
49. M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, and A. Coates Standardisation of spirometry Eur Respir J 26 2005 319 338
50. J.B. Oostenbrink, M.A. Koopmanschap, and F.F. Rutten Standardisation of costs: the Dutch Manual for Costing in economic evaluations Pharmacoeconomics 20 2002 443 454
51. Foundation for Pharmaceutical Statistics/StichtingFarmaceutischeKengetallen (SFK). Available at: www.sfk.nl. Accessed September 22, 2013.
52. Statistics Netherlands, National Organisation for Statistics. Available at: http://statline.cbs.nl/StatWeb. Accessed September 22, 2013.
53. L.M. Lamers, J. McDonnell, P.F. Stalmeier, P.F. Krabbe, and J.J. Busschbach The Dutch tariff: results and arguments for an effective design for national EQ-5d validation studies Health Econ 15 2006 1121 1132
54. D.B. Rubin Multiple imputation for non-response in surveys 1987 Wiley New York
55. A.A. Stinnett, and J. Mullahy Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis Med Decis Making 18 1998 S68 S80
56. S.D. Aaron, D. Fergusson, G.B. Marks, S. Suissa, K.L. Vandemheen, and S. Doucette Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials Thorax 63 2008 122 128
57. S.J. Walters, and J.E. Brazier Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D Qual Life Res 14 2005 1523 1532
58. A.R. Willan Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data Control Clin Trials 22 2001 228 237
59. T.R. Schermer, B.P. Thoonen, G. van den Boom, R.P. Akkermans, R.P. Grol, and H.T. Folgering Randomized controlled economic evaluation of asthma self-management in primary health care Am J Respir Crit Care Med 166 2002 1062 1072
60. M.K. Campbell, S. Thomson, C.R. Ramsay, G.S. MacLennan, and J.M. Grimshaw Sample size calculator for cluster randomized trials Comput Biol Med 34 2004 113 125